A mutant insecticidal protein vip3 and its application

MYPI2025001396A0Undetermined Publication Date: 2024-03-01QINGDAO KINGAGROOT SEED SCI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001396
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-09
Filing Date
2023-08-31
Publication Date
2024-03-01

AI Technical Summary

Technical Problem

The insect resistance problem caused by the Bt insecticidal protein gene used in existing transgenic plants results in low expression and poor insecticidal effect, making it difficult to meet the agricultural demand for efficient insecticide.

Method used

By carrying out point mutations in specific amino acid sequences of the Vip3 family proteins, especially the mutations at the 12th and 14th amino acids, a mutant insecticidal protein Vip3 with high expression and excellent insecticidal effect was obtained, and introduced into plant cells to form Genetically modified plants to increase insect resistance.

Benefits of technology

A mutant Vip3 family insecticidal protein that is highly expressed in plant cells has been achieved, which has excellent insecticidal effects on a variety of pests. It also reduces the toxicity of plant cells and improves the insect-resistant properties of transgenic plants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001396_DRAWING_001
    Figure PI2025001396_DRAWING_001
  • Figure PI2025001396_DRAWING_002
    Figure PI2025001396_DRAWING_002
  • Figure PI2025001396_DRAWING_003
    Figure PI2025001396_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to the field of biotechnology. More specifically, the present invention relates to a mutant insecticidal protein Vip3 and its application. By performing point mutation on each original Vip3 family protein sequence in the present invention, a mutant insecticidal protein Vip3 with reduced plant cytotoxicity and high expression in plant cells is obtained, which has excellent insecticidal effects on various insect pests. Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

A mutant insecticidal protein Vip3 and its application Technical Field

[0001] The present invention relates to the field of biotechnology, and more particularly to a mutant insecticidal protein Vip3 and an application thereof. Background Art

[0002] Agricultural pests are the primary factor impacting crop production. With the rapid development of transgenic technology, the ability to create insect-resistant plants through the transfer of Bt (Bacillus thuringiensis) insecticidal protein genes has revolutionized modern agriculture and increased the importance and value of insecticidal proteins and their genes. Several Bt proteins have been used in transgenic plants to confer insect resistance, including Cry1Ab, Cry1Ac, Cry1F, Cry2Ab, Cry3Bb, and Vip3A. However, with the widespread application of transgenic crops, there remains an urgent need to obtain transgenic plants with high expression levels and effective insect resistance.

[0003] Summary of the Invention

[0004] In order to solve the above-mentioned problems existing in the prior art, the present invention provides a mutant insecticidal protein Vip3, which comprises an amino acid sequence having the following mutations compared with the amino acid sequence of any Vip3 family protein: the 12th amino acid in the amino acid sequence corresponding to SEQ ID NO:4 is mutated to any other amino acid and / or the 14th amino acid is mutated to any other amino acid.

[0005] In a specific embodiment, the mutant insecticidal protein Vip3 comprises an amino acid sequence having the following mutations compared to the amino acid sequence of any Vip3 family protein: the 12th amino acid in the amino acid sequence corresponding to SEQ ID NO:4 is mutated from alanine to glycine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine or histidine; and / or the 14th amino acid is mutated from proline to alanine, glycine, valine, leucine, isoleucine, methionine, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine or histidine.

[0006] In a specific embodiment, the amino acid sequence of the Vip3 family protein is shown as SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28 or SEQ ID NO:30.

[0007] In one embodiment, the mutant insecticidal protein Vip3 comprises an amino acid sequence having the following mutations compared to the amino acid sequence of any Vip3 family protein:

[0008] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to glycine and / or the 14th amino acid is mutated from proline to glutamine;

[0009] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to proline and / or the amino acid at position 14 is mutated from proline to aspartic acid;

[0010] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to asparagine;

[0011] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to leucine;

[0012] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to arginine;

[0013] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to tyrosine and / or the amino acid at position 14 is mutated from proline to lysine;

[0014] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to serine and / or the 14th amino acid is mutated from proline to valine;

[0015] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to histidine and / or the 14th amino acid is mutated from proline to glutamine;

[0016] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to histidine and / or the 14th amino acid is mutated from proline to aspartic acid;

[0017] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to valine and / or the amino acid at position 14 is mutated from proline to cysteine;

[0018] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to proline and / or the 14th amino acid is mutated from proline to glycine;

[0019] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to tryptophan and / or the amino acid at position 14 is mutated from proline to threonine;

[0020] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to aspartic acid;

[0021] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to phenylalanine and / or the amino acid at position 14 is mutated from proline to isoleucine;

[0022] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to alanine;

[0023] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to phenylalanine and / or the 14th amino acid is mutated from proline to histidine;

[0024] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to asparagine and / or the 14th amino acid is mutated from proline to glutamine;

[0025] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glutamine and / or the amino acid at position 14 is mutated from proline to histidine;

[0026] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to proline and / or the amino acid at position 14 is mutated from proline to methionine;

[0027] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to aspartic acid and / or the amino acid at position 14 is mutated from proline to phenylalanine;

[0028] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to histidine and / or the 14th amino acid is mutated from proline to lysine;

[0029] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to phenylalanine and / or the amino acid at position 14 is mutated from proline to methionine;

[0030] The amino acid at position 12 in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to glutamic acid;

[0031] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to isoleucine;

[0032] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to aspartic acid and / or the amino acid at position 14 is mutated from proline to glycine;

[0033] In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to glutamine and / or the 14th amino acid is mutated from proline to valine;

[0034] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to serine and / or the amino acid at position 14 is mutated from proline to glycine;

[0035] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to phenylalanine and / or the amino acid at position 14 is mutated from proline to glycine;

[0036] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to serine;

[0037] In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to arginine and / or the amino acid at position 14 is mutated from proline to methionine;

[0038] The 12th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to histidine;

[0039] The amino acid at position 12 in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to threonine;

[0040] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to cysteine;

[0041] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to valine;

[0042] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to alanine;

[0043] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to aspartic acid;

[0044] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to glutamic acid;

[0045] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to phenylalanine;

[0046] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to histidine;

[0047] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to isoleucine; or

[0048] The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to lysine.

[0049] In another specific embodiment, the amino acid sequence of the mutant insecticidal protein Vip3 is shown in SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, SEQ ID NO: 41-80.

[0050] The present invention also provides an isolated polynucleotide comprising a nucleic acid sequence encoding the mutant insecticidal protein Vip3 or a complementary sequence thereof.

[0051] In one embodiment, the polynucleotide is DNA, RNA, or a hybrid thereof.

[0052] In one embodiment, the polynucleotide is single-stranded or double-stranded.

[0053] In one embodiment, the polynucleotide has a nucleic acid sequence selected from the group consisting of:

[0054] (1) a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, or SEQ ID NO: 29, or SEQ ID NO: 41-80, or a complementary sequence thereof;

[0055] (2) a nucleic acid sequence as shown in any one of SEQ ID NO: 2, SEQ ID NO: 31-40, SEQ ID NO: 81-120, or a complementary sequence thereof;

[0056] (3) a nucleic acid sequence that hybridizes to the sequence shown in (1) or (2) under stringent conditions; and / or

[0057] (4) A nucleic acid sequence encoding the same amino acid sequence as the sequence shown in (1) or (2) due to the degeneracy of the genetic code, or a complementary sequence thereof.

[0058] In another embodiment, the nucleic acid sequence is optimized for expression in plant cells.

[0059] The present invention also provides an expression vector, which comprises the polynucleotide and an expression control element operably linked thereto.

[0060] The present invention also provides an expression vector, which comprises a tandem gene expression frame for expressing the mutant insecticidal proteins Vip3 and Pat.

[0061] In a specific embodiment, the nucleotide sequence of the mutated insecticidal protein Vip3 is any one of SEQ ID NO: 2, SEQ ID NO: 31-40, and SEQ ID NO: 81-120, and the nucleotide sequence of the gene Pat is SEQ ID NO: 6.

[0062] In another specific embodiment, the gene tandem expression cassette further comprises:

[0063] The nucleotide sequence of CaMV 35S promoter for initiating Pat expression is shown in SEQ ID NO: 5, and the nucleotide sequence of CaMV poly(A) signal for terminating gene expression is shown in SEQ ID NO: 7;

[0064] The nucleotide sequence is shown in SEQ ID NO: 8 as the promoter OsUbi2 promoter for initiating the expression of the mutant insecticidal protein Vip3, the nucleotide sequence is shown in SEQ ID NO: 3 as the chloroplast leader peptide CTP-TS-SSU, and the nucleotide sequence is shown in SEQ ID NO: 9 as the terminator T-Ara5 for terminating the expression of the gene.

[0065] In another specific embodiment, the nucleotide sequence of the expression vector is shown in SEQ ID NO: 10.

[0066] The present invention also provides a host cell, which contains the polynucleotide or the expression vector.

[0067] In one embodiment, the host cell is a plant cell.

[0068] The present invention also provides a method for cultivating transgenic plants with or enhanced insect resistance and plants produced by the method, which comprises regenerating the plant cells into plants.

[0069] The present invention also provides the use of the expression vector or the host cell in improving the insect-resistant properties of plants, preparing medicaments with insect-resistant effects, or cultivating transgenic plants with or enhanced insect-resistant capabilities.

[0070] The present invention also provides a method for managing insect resistance or controlling insects, which comprises contacting an insect with at least the above-mentioned plant, wherein the insect contacts at least the mutant insecticidal protein Vip3 by feeding on the tissue of the plant, and after contact, the growth of the insect is inhibited and / or the insect dies, thereby achieving management of the insect resistance or control of the insect damage to the plant.

[0071] In one embodiment, the plant is corn, cotton or soybean.

[0072] In one embodiment, the insecticide is lepidopteran or the insect is lepidopteran.

[0073] The present invention obtains a mutant Vip3 family insecticidal protein with reduced toxicity to plant cells by performing point mutation on the original Vip3 family protein sequence, which can be highly expressed in plant cells and has excellent insecticidal effects on various pests.

[0074] Detailed Description of the Invention

[0075] Some terms used in this specification are defined below.

[0076] In the present invention, "plant" is understood to be any differentiated multicellular organism capable of photosynthesis, in particular monocotyledonous or dicotyledonous plants.

[0077] In the present invention, the term "plant tissue" or "plant part" includes plant cells, protoplasts, plant tissue culture, plant callus, plant pieces, as well as plant embryos, pollen, ovules, seeds, leaves, stems, flowers, branches, seedlings, fruits, kernels, ears, roots, root tips, anthers, etc.

[0078] In the present invention, "plant cell" is understood to be any cell from or found in a plant, which is capable of forming, for example, undifferentiated tissue such as callus, differentiated tissue such as embryos, plant components, plants or seeds.

[0079] In the present invention, "host organism" should be understood as any unicellular or multicellular organism into which mutant protein-encoding nucleic acids can be introduced, including, for example, bacteria such as Escherichia coli, fungi such as yeast (e.g., Saccharomyces cerevisiae), molds (e.g., Aspergillus), plant cells and plants, etc.

[0080] The terms "protein," "polypeptide," and "peptide" are used interchangeably herein to refer to a polymer of amino acid residues, including polymers in which one or more amino acid residues is a chemical analog of a naturally occurring amino acid residue. The proteins and polypeptides of the present invention can be produced recombinantly or by chemical synthesis.

[0081] Specific amino acid positions (numbers) within the proteins of the present invention are determined by aligning the amino acid sequence of the target protein with Vip3Aa using standard sequence alignment tools, such as the Smith-Waterman algorithm or the CLUSTALW2 algorithm, wherein the sequences are considered aligned when the alignment score is the highest. The alignment score can be calculated according to the method described in Wilbur, WJ and Lipman, DJ (1983) Rapid similarity searches of nucleic acid and protein data banks. Proc. Natl. Acad. Sci. USA, 80:726-730. The default parameters for the ClustalW2 (1.82) algorithm are preferably used: protein gap open penalty = 10.0; protein gap extension penalty = 0.2; protein matrix = Gonnet; protein / DNA end gap = -1; protein / DNA GAPDIST = 4.

[0082] Preferably, the AlignX program (part of the vectorNTI suite) is used with default parameters suitable for multiple alignment (gap opening penalty: 10; gap extension penalty: 0.05) to determine the position of specific amino acids within the protein of the present invention by aligning the amino acid sequence of the protein with Vip3Aa.

[0083] Amino acid sequence identity can be determined conventionally using the BLAST algorithm (Altschul et al., 1990, Mol. Biol. 215:403-10) available from the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ) using default parameters.

[0084] It is also clear to those skilled in the art that the structure of a protein can be changed without adversely affecting its activity and functionality, for example, one or more conservative amino acid substitutions can be introduced into the amino acid sequence of a protein without adversely affecting the activity and / or three-dimensional configuration of the protein molecule. Examples and embodiments of conservative amino acid substitutions are clear to those skilled in the art. Specifically, an amino acid residue can be replaced with another amino acid residue belonging to the same group as the site to be replaced, i.e., a non-polar amino acid residue can be substituted for another non-polar amino acid residue, a polar uncharged amino acid residue can be substituted for another polar uncharged amino acid residue, a basic amino acid residue can be substituted for another basic amino acid residue, and an acidic amino acid residue can be substituted for another acidic amino acid residue. Conservative substitutions in which one amino acid is replaced by another amino acid belonging to the same group fall within the scope of the present invention as long as the substitution does not impair the biological activity of the protein.

[0085] Therefore, in addition to the aforementioned mutations, the mutant proteins of the present invention may also include one or more other mutations, such as conservative substitutions, in the amino acid sequence. Furthermore, the present invention also encompasses mutant proteins that include one or more other non-conservative substitutions, as long as the non-conservative substitutions do not significantly affect the desired function and biological activity of the protein of the present invention.

[0086] As is well known in the art, one or more amino acid residues can be deleted from the N and / or C terminus of a protein while still retaining its functional activity. Therefore, on the other hand, the present invention also relates to fragments in which one or more amino acid residues are deleted from the N and / or C terminus of a mutant protein while retaining its desired functional activity, which are also within the scope of the present invention and are referred to as biologically active fragments. In the present invention, a "biologically active fragment" refers to a portion of a mutant protein of the present invention that retains the biological activity of the mutant protein of the present invention. For example, a biologically active fragment of a mutant protein can be a portion in which one or more (e.g., 1-50, 1-25, 1-10 or 1-5, such as 1, 2, 3, 4 or 5) amino acid residues are deleted from the N and / or C terminus of the protein, but which still retains the biological activity of the full-length protein.

[0087] The terms "Vip3 family protein", "Vip3 family gene" and "Vip3" are the result of classifying Vip (vegetative insecticidal protein) proteins based on amino acid sequence homology, including genes such as vip3A, vip3B and vip3C.

[0088] In a specific embodiment, the amino acid sequence of the Vip3 family protein is shown as SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28 or SEQ ID NO:30.

[0089] The term "mutation" refers to a single amino acid variation in a polypeptide and / or at least a single nucleotide variation in a nucleic acid sequence relative to the canonical or wild-type sequence or a reference sequence.

[0090] The terms "polynucleotide," "nucleic acid," "nucleic acid molecule," or "nucleic acid sequence" are used interchangeably to refer to oligonucleotides, nucleotides, or polynucleotides, and fragments or portions thereof, which may be single-stranded or double-stranded and represent the sense or antisense strand. Nucleic acids include DNA, RNA, or hybrids thereof, and may be of natural or synthetic origin. For example, a nucleic acid may include mRNA or cDNA. A nucleic acid may include a nucleic acid that has been amplified (e.g., using the polymerase chain reaction). The nucleotide designations "R" refer to a purine such as guanine or adenine; "Y" refers to a pyrimidine such as cytosine or thymine (uracil in the case of RNA); "M" refers to adenine or cytosine; "K" means guanine or thymine; and "W" means adenine or thymine.

[0091] The term "isolated", when referring to a nucleic acid, refers to a nucleic acid that is separated from a substantial portion of the genome in which it is naturally present and / or substantially separated from other cellular components that naturally accompany the nucleic acid. For example, any nucleic acid that has been produced by synthesis (e.g., by continuous base condensation) is considered to be isolated. Similarly, recombinantly expressed nucleic acids, cloned nucleic acids, nucleic acids produced by primer extension reactions (e.g., PCR), or nucleic acids that have otherwise been excised from a genome are also considered to be isolated.

[0092] It is well known to those skilled in the art that, due to the degeneracy of the genetic code, a variety of different nucleic acid sequences can encode the amino acid sequences disclosed herein. Generating alternative nucleic acid sequences encoding the same protein is within the capabilities of those skilled in the art, and thus, the present invention encompasses nucleic acid sequences encoding the same amino acid sequence due to the degeneracy of the genetic code. For example, to achieve high expression of a heterologous gene in a target host organism, such as a plant, the gene can be optimized using codons preferred by the host organism to achieve better expression.

[0093] The term "transgenic" plant refers to a plant comprising a heterologous polynucleotide. Preferably, the heterologous polynucleotide is stably integrated in the genome so that the polynucleotide is passed to successive generations. The heterologous polynucleotide can be integrated into the genome separately or integrated as a part of a recombinant expression cassette." transgenic" is used herein to refer to any cell, cell line, callus, tissue, plant part or plant, whose genotype is changed due to the presence of heterologous nucleic acids, including those initially changed transgenic organisms or cells, and those produced from initial transgenic organisms or cell hybridization or asexual reproduction. As used herein, the term "transgenic" is not intended to include changing genomes (chromosomes or chromosomes) by conventional plant breeding methods (for example, hybridization) or by naturally occurring events (such as, self-fertilization, random cross fertilization, non-recombinant virus infection, non-recombinant bacterial transformation, non-recombinant transposition or spontaneous mutation).

[0094] The herbicide-resistant Pat gene and Vip3 family gene herein can be introduced into plants according to methods commonly used in the industry, and can be subjected to transgenic manipulation via appropriate plant transformation expression vectors.

[0095] The selection of any appropriate promoter, including vectors, is a common practice in the industry for plant transgenics. For example, commonly used promoters in plant transgenics include, but are not limited to, the SP6 promoter, the T7 promoter, the T3 promoter, the PM promoter, the maize ubiquitin promoter, the cauliflower mosaic virus (CaMV) 35S promoter, the nopaline synthase (nos) promoter, the figwort mosaic virus 35S promoter, the sugarcane stalk-shaped virus promoter, the bamboo yellow mottle virus promoter, the light-inducible promoter ribulose-1,5-ketose carboxylase (ssRUBISCO small subunit), the rice cytoplasmic triosephosphate isomerase (TPI) promoter, the Arabidopsis adenine phosphoribosyltransferase (APRT) promoter, the octopine synthase promoter, and the BCB (blue copper binding protein) promoter.

[0096] Plant transgenic vectors include a polyadenylation signal sequence that can cause 3'-end polyadenylation, including, but not limited to, the NOS 3'-terminal derivative of the nopaline synthase gene of Agrobacterium tumefaciens, the octopine synthase 3'-terminal derivative of the octopine synthase gene of Agrobacterium tumefaciens, the 3'-terminal end of the tomato or potato protease inhibitor I or II gene, the CaMVPoly A signal sequence, the 3'-terminal end of the rice α-amylase gene, and the 3'-terminal end of the phaseolin gene.

[0097] The vector also includes a gene encoding a selectable marker as a reporter molecule. Examples of selectable markers include, but are not limited to, antibiotics (e.g., neomycin, carbenicillin, kanamycin, spectinomycin, hygromycin, bleomycin, chloramphenicol, etc.) or herbicide resistance (glyphosate, glufosinate, glufosinate, etc.) genes.

[0098] Vector transformation methods include Agrobacterium-mediated transformation, electroporation, microparticle bombardment, polyethylene glycol-medium absorption, and the like to introduce recombinant plasmids into plants.

[0099] The plant transformation recipients of the present invention include plant cells (including suspension culture cells), protoplasts, callus tissues, hypocotyls, seeds, cotyledons, buds and mature plants.

[0100] The scope of transgenic plants includes not only the plants obtained at the time of gene introduction, but also its clones and offspring (T1 generation, T2 generation or subsequent generations). The scope of the present invention also includes all mutants and variants of the above-mentioned transgenic plants that show the characteristics of the first generation transgenic plants after hybridization and fusion. The scope of the present invention also includes plant parts, such as seeds, flowers, stems, fruits, leaves, roots, tubers, and tuberous stems, which are derived from plants that have been genetically modified in advance by the methods mentioned in the present invention, or their offspring, and are composed of at least a portion of genetically modified cells.

[0101] As used herein, "insecticide" or "insect-resistant" refers to being toxic to crop pests, thereby achieving "control" and / or "prevention" of crop pests. Preferably, "insecticide" or "insect-resistant" refers to killing crop pests. These pests include Lepidoptera, such as corn borer and / or fall armyworm.

[0102] As used herein, "inhibition of insect growth" refers to sublethal effects, meaning effects that are not lethal but induce certain effects on growth, development, behavior, physiology, biochemistry, and tissue, such as slowed and / or stopped growth. Furthermore, the plants should be morphologically normal and can be cultivated under conventional methods for product consumption and / or production.

[0103] The present invention can be implemented in a variety of different forms, and the implementation methods are not limited to the methods described herein. The examples herein are provided for thorough and complete effectiveness, so that those skilled in the art can fully understand the scope of the present invention. The same reference numbers refer to the same elements throughout the present invention.

[0104] The terms used herein are intended to describe specific embodiments and are not intended to set limitations. Unless otherwise expressly stated herein, the terms "a," "an," and "the" used in the above English version also include their plural forms. The terms "comprises" and / or "comprising," or "includes" and / or "including" used herein specifically refer to the presence of the features, factors, and / or components described herein, and do not exclude the presence or addition of one or more other features, factors, and components. The term "and / or" used in the above includes all items in the one or more combination list.

[0105] The present invention has been described in detail through a series of embodiments, but the present invention is not limited to the disclosed embodiments. Any quantitative changes, substitutions, replacements, etc. within the scope of the present invention are not described herein, or may be modified according to public needs. BRIEF DESCRIPTION OF THE DRAWINGS

[0106] Figure 1 is a schematic diagram of the pQYI0187 vector.

[0107] FIG2 is a comparison of plant cytotoxicity in transgenic maize QYI186 (transgenic MIR162 Vip3Aa, top) and QYI187 (transgenic Vip3Aa-K1, bottom) calli after 4 weeks of differentiation.

[0108] FIG3 is a comparison of the phytotoxicity of other Vip3Aa protein mutants.

[0109] Figure 4 shows the mortality of Spodoptera frugiperda larvae at different dilutions of freeze-dried leaf powder of transgenic corn QYI187 and QYI186. The left figure shows QYI187 diluted 50 times, and the right figure shows QYI186 diluted 4 times.

[0110] Figure 5 shows representative results of a feeding experiment with cotton bollworms using non-transgenic and transgenic soybean leaves. The left image shows a non-transgenic wild-type recipient soybean leaf, and the right image shows a Vip3Aa-K1 transgenic soybean leaf.

[0111] Sequence Description DETAILED DESCRIPTION

[0112] The following examples are presented so as to provide those skilled in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent or imply that the experiments below are all or the only experiments performed. It should be understood by those skilled in the art that many variations and / or modifications may be made to the invention shown in the specific aspects without departing from the spirit or scope of the invention as broadly described. Therefore, this disclosure is to be considered in all respects as illustrative and not restrictive.

[0113] Example 1: Construction of corn transgenic vector

[0114] Based on the Vip3Aa sequence information listed on the Bt gene nomenclature website (http: / / www.lifesci.sussex.ac.uk / home / Neil_Crickmore / Bt / vip.html), the Vip3Aa protein sequence (GenBank: ABG20429.1, amino acid sequence shown in SEQ ID NO: 4) that performs well in transgenic maize mir162 was selected. After protein structure prediction, position 12 of the amino acid sequence was mutated from Ala to Gly, and position 14 from Pro to Gln. The protein was named Vip3Aa-K1, and its amino acid sequence is shown in SEQ ID NO: 1. This amino acid sequence was codon-optimized for maize, and the corresponding coding nucleotide sequence is shown in SEQ ID NO: 2, which consists of 2367 nucleotides and encodes 789 amino acids. The nucleotide sequence was synthesized by GenScript Biotech.

[0115] When the Vip3Aa-K1 gene sequence was artificially synthesized, a chloroplast localization peptide CTP-TS-SSU was simultaneously synthesized upstream of the ATG. The nucleotide sequence of this peptide is shown in SEQ ID NO: 3. The artificially synthesized CTP-TS-SSU-Vip3Aa-K1 gene fragment was constructed downstream of the rice Ubiquitin2 promoter and upstream of the T-Ara5 terminator to obtain a Vip3Aa-K1 gene expression cassette driven by the OsUbi2 promoter. The Vip3Aa-K1 gene expression cassette was then inserted into a vector containing the Pat gene by homologous recombination seamless cloning to obtain an expression cassette containing the insect-resistant gene Vip3Aa-K1 and the glufosinate-tolerance gene Pat. The two expression cassettes were then ligated between the LB and RB regions of the pCAMBIA1300 backbone by homologous recombination to construct the vector pQYI0187 ( FIG. 1 ).

[0116] The vector pQYI0186 was constructed according to the above method. The difference between pQYI0186 and pQYI0187 is that Vip3Aa-K1 is replaced by MIR162 Vip3Aa.

[0117] Ten representative Vip3 family protein sequences (SEQ ID NOs: 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30) were selected. The amino acid position 2 of SEQ ID NO: 11 (corresponding to position 14 in the amino acid sequence of SEQ ID NO: 4) was mutated from Pro to Gln. For the remaining nine sequences, position 12 was mutated from Ala to Gly, and position 14 was mutated from Pro to Gln. The resulting amino acid sequences are shown in SEQ ID NOs: 11, 13, 15, 17, 19, 21, 23, 25, 27, and 29, respectively. The above proteins and mutant proteins were constructed into vectors pQYI0011-pQYI0030 according to the construction method of vector pQYI0187.

[0118] Site-directed saturation mutations were also generated separately or simultaneously at amino acid positions 12 and / or 14 of SEQ ID NO: 4. In addition to SEQ ID NO: 1, this method generated a total of 398 new amino acid sequences. Following the construction of vector pQYI0186, these 398 amino acid sequences were codon-optimized for maize to construct double-point mutation and single-point mutation vectors for maize immature embryonic callus transformation.

[0119] Example 2: Comparison of cytotoxicity of transgenic plants

[0120] The transgenic vectors pQYI0187 and pQYI0186 were transformed into maize callus using Agrobacterium tumefaciens. Transformants QYI187 and QYI186 were obtained through screening and culture. During the genetic transformation process, the emergence of intermediate materials from maize transformants QYI187 and QYI186 was compared.

[0121] Table 1 Positive transformation seedlings of QYI187 and QYI186

[0122] The results showed that callus growth of the QYI186 transformant was severely inhibited and harmed, with only 60 positive seedlings out of 1000 transformed embryos. In contrast, callus growth of the QYI187 transformant was excellent, with 630 positive seedlings out of 1000 transformed embryos (see Figure 2 and Table 1). This suggests that the QYI187 (Vip3Aa-K1) transgenic material significantly reduced its phytotoxicity to recipient plants.

[0123] Similarly, the transgenic vector pQYI0011-pQYI0030 was transformed into maize callus using Agrobacterium tumefaciens. Transformants QYI11-QYI30 were obtained after screening and culture. During the transformation process, seedling emergence of intermediate materials from the maize QYI11-QYI30 transformants was compared. The results showed that callus growth of the unmutated QYI12 and QYI14 transformants was severely inhibited and compromised, with only a small number of positively transformed seedlings (58 and 75 per 1000 immature embryos, respectively). In contrast, callus growth of the QYI11 and QYI13 transformants containing the mutant proteins was excellent, with 614 and 571 positively transformed seedlings per 1000 immature embryos, respectively. This suggests that the transgenic materials containing the mutant proteins, QYI11 (double mutation of the Vip3Aa truncated protein) and QYI13 (double mutation of the Vip3Aa19 protein), significantly reduced their phytotoxicity to recipient plants. Similarly, transgenic materials with other mutant Vip3 family proteins (QYI15, QYI17, QYI19, QYI21, QYI23, QYI25, QYI27 and QYI29) also showed significantly reduced plant cytotoxicity.

[0124] In addition, the intermediate materials of the transformants of the double-point mutation and single-point mutation vectors constructed in Example 1 were also compared. The results showed that the number of positive seedlings exceeded that of QYI186, and the cytotoxicity of the mutants to plants was reduced. When the amino acid at position 12 and / or position 14 of Vip3Aa (SEQ ID NO: 4) was mutated to 12P / 14D, 12G / 14N, 12G / 14L, 12G / 14R, 12Y / 14K, 12S / 14V, 12H / 14Q, 12H / 14D, 12V / 14C, 12P / 14G, 12W / 14T, 12G / 14D, 12F / 14I, 12G / 14A, 14V, 12F / 14H, 14C, 12N / 14Q, 12Q / 14H, 12P / 14M, 12D / 14F, 12 When H / 14K, 12F / 14M, 12E, 12G / 14I, 12D / 14G, 12Q / 14V, 12S / 14G, 12F / 14G, 12G / 14S, 12R / 14M, 12H, 12T, 14A, 14D, 14E, 14F, 14H, 14I, and 14K were used, a large number of positive seedlings were obtained (338 to 626 positive transformed seedlings per 1000 transformed embryos), and the intermediate material of the transformants grew normally on the screening culture dishes, indicating that the cytotoxicity to the recipient plants was significantly reduced. Representative phytotoxicity comparison images are shown in Figure 3.

[0125] Example 3: Detection of protein content and insecticidal activity in transgenic corn leaves

[0126] Protein expression levels were measured at the V7-V8 stage of the T2 generation of transgenic corn. The average expression level of Vip3Aa-K1 in the leaves of transgenic corn QYI187 reached 130 μg / g (fresh weight of leaves), while the average expression level of MIR162Vip3Aa in the leaves of transgenic corn QYI186 was 11 μg / g (fresh weight of leaves). Tests also revealed that the expression levels of the corresponding mutant proteins in other transgenic corn varieties were significantly higher than those in the corresponding transgenic corn containing the original protein.

[0127] Cut the upper leaves of the test corn plants of QYI186 and QYI187 T2 generations at the V7-V8 leaf stage with the same growth status, put them into the corresponding marked seal bags, take them back to the laboratory, and cut the leaves into 2 cm 2 Different sizes of the feed were placed in separate mortars and ground with liquid nitrogen. Freeze-dried leaf powder was diluted at 4x and 50x dilution ratios, respectively. When the prepared feed temperature dropped to 45°C, freeze-dried leaf powder was added proportionally and mixed evenly. After thorough cooling, round feed cakes of uniform shape and weight were formed using a fixed film mold and placed in bioassay devices. Ten replicates were set up, with one second-instar larva of Spodoptera frugiperda in each device. The experiment was conducted in an insectary at 27±1°C, 75% relative humidity, and a L:D ratio of 16h:8h. Larvae mortality in each device was assessed after 7 days.

[0128] Second-instar larvae of Spodoptera frugiperda from 10 repeated experiments were collected into an experimental device. The results are shown in Figure 4. The insecticidal protein concentrations of QYI187 diluted 50 times and QYI186 diluted 4 times were 2.6 μg / g (fresh weight of feed) and 2.75 μg / g (fresh weight of feed), respectively. The concentrations of Vip3Aa-K1 and Vip3Aa contained in them were equivalent, and the mortality rate of second-instar larvae of Spodoptera frugiperda was 100%.

[0129] In addition, the LC50 of each original protein and each mutant protein against Spodoptera frugiperda was determined using the feed surface method. Freshly prepared artificial feed was poured into a beaker and soaked in hot water. The feed was then dispensed into a 24-well cell culture plate using a manual continuous dispenser, with 1 mL of feed dispensed into each well. The wells had a diameter of 1.6 cm. After the feed solidified, the resulting surface area was 2 cm. 2. The mutant protein to be tested was gradiently diluted with Na2CO3 / NaHCO3 buffer (pH=10) to 4 concentrations. Use a manual continuous dispenser to dispense the above concentration dilutions, dispense 50μl into each well and shake well to ensure that the protein covers the entire surface of the feed. After the addition is completed, the 24-well cell culture plate is placed in a clean bench to air dry. After the protein has completely penetrated into the surface of the feed, the second-instar larvae of the fall armyworm are inoculated. One head is inoculated into each well, the lid is covered, tied tightly, and placed at a temperature of 25-27°C, a relative humidity of 65-70%, and a light L / D of 16h / 8h. 50μl of buffer solution was added as a control, and the test was repeated twice. After 7 days, the death of each group of test insects was observed, the insect mortality rate was calculated, and the corresponding lethal concentration LC50 was obtained. The results showed that the LC50 value of the mutant protein of the present application was not significantly different from that of its corresponding Vip3 original protein, and the insecticidal effect on the fall armyworm was maintained or even improved. Representative data are shown in Table 2.

[0130] Table 2 Data on the median lethal concentration (LC50) of some Vip3 mutant proteins against Spodoptera frugiperda

[0131] Example 4: Detection of insect resistance effect of transgenic soybean leaves

[0132] Based on the same method as in Example 1, a soybean transgenic vector containing Vip3Aa-K1 was constructed and transformed into a soybean recipient to obtain transgenic soybeans. The upper leaves of the test soybean plants with the same growth status were taken and placed in a sealed bag with the corresponding name. The leaves were taken back to the laboratory and cut into 2 cm 2 The animals were placed in bioassay devices, each containing three second-instar larvae of cotton bollworm (H. armigera) for 10 replicates. The experiment was conducted in an insectary at 27 ± 1°C, 75% relative humidity, and a L:D ratio of 16 h:8 h. After 6 days, larval mortality and leaf feeding activity were assessed in each device.

[0133] The experimental results showed that non-transgenic soybean leaves were heavily infested by cotton bollworm larvae, and the larvae grew well. However, leaves of Vip3Aa-K1 transgenic soybeans were largely uninfested, and the larvae that did infest them all died. This suggests that Vip3Aa-K1 transgenic soybean plants exhibit a strong resistance phenotype to cotton bollworm larvae, as shown in Figure 5.

[0134] At the same time, after many tests, it was found that the transgenic plants containing Vip3Aa-K1 protein described in the present invention (including but not limited to corn, cotton, soybean, etc.) also showed similar insect-resistant effects in tests on other Lepidoptera plant pests such as Spodoptera, Striacosta, Spodoptera, Cercopithecus, Spodoptera, and Elasmopalpus. In addition, other mutated Vip3 family proteins also have excellent insecticidal effects on various pests and have low toxicity to plant cells.

[0135] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not limiting. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention.

Claims

1. A mutant insecticidal protein Vip3, comprising an amino acid sequence having the following mutations compared to the amino acid sequence of any Vip3 family protein: the amino acid at position 12 in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated to any other amino acid and / or the amino acid at position 14 is mutated to any other amino acid.

2. The mutant insecticidal protein Vip3 according to claim 1, characterized in that It comprises an amino acid sequence having the following mutations compared to any Vip3 family protein amino acid sequence: the 12th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to glycine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine or histidine; and / or the 14th amino acid is mutated from proline to alanine, glycine, valine, leucine, isoleucine, methionine, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine or histidine.

3. The mutant insecticidal protein Vip3 according to claim 1 or 2, characterized in that The amino acid sequence of the Vip3 family protein is shown in SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28 or SEQ ID NO:

30.

4. The mutant insecticidal protein Vip3 according to any one of claims 1 to 3, comprising an amino acid sequence having the following mutations compared to the amino acid sequence of any Vip3 family protein: In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to glycine and / or the 14th amino acid is mutated from proline to glutamine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to proline and / or the amino acid at position 14 is mutated from proline to aspartic acid; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to asparagine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to leucine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to arginine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to tyrosine and / or the amino acid at position 14 is mutated from proline to lysine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to serine and / or the 14th amino acid is mutated from proline to valine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to histidine and / or the 14th amino acid is mutated from proline to glutamine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to histidine and / or the 14th amino acid is mutated from proline to aspartic acid; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to valine and / or the amino acid at position 14 is mutated from proline to cysteine; The amino acid at position 12 in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to proline and / or the 14th amino acid is mutated from proline to glycine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to tryptophan and / or the amino acid at position 14 is mutated from proline to threonine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to aspartic acid; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to phenylalanine and / or the amino acid at position 14 is mutated from proline to isoleucine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to alanine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to phenylalanine and / or the 14th amino acid is mutated from proline to histidine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to asparagine and / or the 14th amino acid is mutated from proline to glutamine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to glutamine and / or the 14th amino acid is mutated from proline to histidine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to proline and / or the amino acid at position 14 is mutated from proline to methionine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to aspartic acid and / or the amino acid at position 14 is mutated from proline to phenylalanine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to histidine and / or the 14th amino acid is mutated from proline to lysine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to phenylalanine and / or the amino acid at position 14 is mutated from proline to methionine; The amino acid at position 12 in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to glutamic acid; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to isoleucine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to aspartic acid and / or the amino acid at position 14 is mutated from proline to glycine; In the amino acid sequence corresponding to SEQ ID NO: 4, the 12th amino acid is mutated from alanine to glutamine and / or the 14th amino acid is mutated from proline to valine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to serine and / or the amino acid at position 14 is mutated from proline to glycine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to phenylalanine and / or the amino acid at position 14 is mutated from proline to glycine; In the amino acid sequence corresponding to SEQ ID NO: 4, the amino acid at position 12 is mutated from alanine to glycine and / or the amino acid at position 14 is mutated from proline to serine; The amino acid at position 12 in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to arginine and / or the 14th amino acid is mutated from proline to methionine; The 12th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to histidine; The amino acid at position 12 in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from alanine to threonine; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to cysteine; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to valine; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to alanine; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to aspartic acid; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to glutamic acid; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to phenylalanine; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to histidine; The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to isoleucine; or The 14th amino acid in the amino acid sequence corresponding to SEQ ID NO: 4 is mutated from proline to lysine.

5. The mutant insecticidal protein Vip3 according to any one of claims 1 to 4, whose amino acid sequence is shown in SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27 or SEQ ID NO: 29, SEQ ID NOs: 41-80.

6. An isolated polynucleotide comprising a nucleic acid sequence encoding the mutant insecticidal protein Vip3 according to any one of claims 1 to 5 or a complementary sequence thereof.

7. The polynucleotide according to claim 6, characterized in that The polynucleotide is DNA, RNA or a hybrid thereof.

8. The polynucleotide according to claim 6 or 7, characterized in that The polynucleotide is single-stranded or double-stranded.

9. The polynucleotide according to any one of claims 6 to 8, characterized in that It has a nucleic acid sequence selected from the group consisting of: (1) a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, or SEQ ID NO: 29, or SEQ ID NO: 41-80, or a complementary sequence thereof; (2) a nucleic acid sequence as shown in any one of SEQ ID NO: 2, SEQ ID NO: 31-40, SEQ ID NO: 81-120, or a complementary sequence thereof; (3) a nucleic acid sequence that hybridizes to the sequence shown in (1) or (2) under stringent conditions; and / or (4) A nucleic acid sequence encoding the same amino acid sequence as the sequence shown in (1) or (2) due to the degeneracy of the genetic code, or a complementary sequence thereof.

10. The polynucleotide of claim 9, wherein the nucleic acid sequence is optimized for expression in plant cells.

11. An expression vector comprising the polynucleotide according to any one of claims 6 to 10 and an expression control element operably linked thereto.

12. An expression vector comprising a tandem expression cassette for expressing the mutant insecticidal protein Vip3 and Pat according to claim 1; preferably, the nucleotide sequence of the mutant insecticidal protein Vip3 gene is any one of SEQ ID NO: 2, SEQ ID NO: 31-40, and SEQ ID NO: 81-120, and the nucleotide sequence of the gene Pat is SEQ ID NO:

6.

13. The expression vector according to claim 12, wherein the gene tandem expression cassette further comprises: The nucleotide sequence of CaMV 35S promoter for initiating Pat expression is shown in SEQ ID NO: 5, and the nucleotide sequence of CaMV poly(A) signal for terminating gene expression is shown in SEQ ID NO: 7; The promoter OsUbi2 promoter for initiating expression of the mutant insecticidal protein Vip3 as shown in SEQ ID NO: 8, the chloroplast leader peptide CTP-TS-SSU as shown in SEQ ID NO: 3, and the terminator T-Ara5 as shown in SEQ ID NO: 9 for terminating gene expression; Preferably, the nucleotide sequence of the expression vector is shown in SEQ ID NO:

10.

14. A host cell comprising the polynucleotide according to any one of claims 6 to 10 or the expression vector according to any one of claims 11 to 13, preferably, the host cell is a plant cell.

15. A method for cultivating a transgenic plant having or improving insect resistance and a plant produced by said method, comprising regenerating the plant cell according to claim 14 into a plant.

16. Use of the expression vector according to any one of claims 11 to 13 or the host cell according to claim 14 for improving insect resistance in plants, preparing an insect-resistant agent, or cultivating transgenic plants with or enhanced insect resistance; wherein the plant is preferably corn, cotton, or soybean, and the insect resistance is preferably lepidopteran resistance.

17. A method of managing insect resistance or controlling insects, characterized in that The method comprises contacting an insect with at least the plant of claim 15, wherein the insect contacts at least the mutant insecticidal protein Vip3 by feeding on the tissue of the plant, and the growth of the insect is inhibited and / or the insect dies after contact, thereby achieving management of the resistance of the insect or control of the damage to the plant by the insect; wherein the plant is preferably corn, cotton or soybean, and the insect is preferably Lepidoptera.